Recent Material Events - Acorda Therapeutics (ACOR)

Filing Date	Description
2008-08-19	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2008-08-07	On August 6, 2008, Acorda Therapeutics, Inc. (the “Registrant”) entered into an underwriting agreement (the “Underwriting Agreement”) with Deutsche Bank Securities Inc. ( the “Underwriter”), relating to the issuance and ...
2008-08-05	On August 5, 2008, Acorda Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2008. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorpora ...
2008-06-02	On June 2, 2008, Acorda Therapeutics, Inc. issued a press release announcing the results of its second Phase 3 clinical study of Fampridine-SR on walking ability in people with multiple sclerosis. A copy of the press release is attached as Exhibit 99 ...
2008-05-05	On May 5, 2008, Acorda Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2008. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated ...
2008-04-04	On March 25, 2008, Acorda Therapeutics, Inc. (the “Registrant”) and the National MS Society released the results of two 2008 surveys on the impact of mobility loss on people with multiple sclerosis conducted by Harris Interactive on behalf ...
2008-03-19	On March 17, 2008, Ron Cohen, President and Chief Executive Officer of Acorda Therapeutics, Inc. (the “Company”) adopted a pre-arranged trading plan (the “Plan”). The Plan was designed to comply with Rule 10b5-1 under the Securiti ...
2008-02-14	On February 12, 2008, Acorda Therapeutics, Inc. (the “Registrant”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities Inc. and Deutsche Bank Securities Inc., as representatives of the ...
2008-02-11	On February 11, 2008, Acorda Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and the full year ended December 31, 2007. A copy of the press release is attached as Exhibit 99.1 to this Current Report o ...
2008-02-06	Gross sales of Zanaflex Capsules and tablets were approximately $12 million for the quarter ended December 31, 2007 and approximately $43 million for the year ended December 31, 2007. Zanaflex Capsules and tablets operations were cash flow neutral in ...